|
Canada-0-Insurance ไดเรกทอรีที่ บริษัท
|
ข่าว บริษัท :
- Reinvigorating COTL1high NK cells via GITR signalling . . . - PubMed
Here we identify a COTL1 high natural killer (NK) subset that mediates ICB responsiveness in these patients Mechanistically, PD-L1 + macrophages coexpress GITRL and engage GITR on COTL1 high NK cells, whereas PD-L1 blockade relieves the PD-1-mediated inhibition of GITR signalling and promotes NK cell activation
- 激活GITR信号，重振COTL1highNK细胞，可克服肿瘤特异 . . .
《Nature Cell Biology》：Reinvigorating COTL1high NK cells via GITR signalling overcomes immune checkpoint blockade resistance in tsMHC-I-impaired tumours
- GitHub - youwh1996 HCC_NK_PAPER
The code used in Paper 'Reinvigorating COTL1high NK Cells via GITR Signaling Overcomes Immune Checkpoint Blockade Resistance in tsMHC-I-impaired Tumors'
- Reprogramming NK cells and macrophages via combined antibody and . . .
Wang et al report an immune priming therapy based on a single dose of anti-tumor antibodies, IL-2, and anti-PD-1, which engages natural killer cells and macrophages, promotes lymphocyte recruitment and activation, and elicits vascular normalization
- Reinvigorating COTL1high NK cells via GITR signalling . . .
Reinvigorating COTL1high NK cells via GITR signalling overcomes immune checkpoint blockade resistance in tsMHC-I-impaired tumours - 科研通
- COTL1high NK cells are key determinants of checkpoint blockade . . .
LabWaggoner (Waggoner Lab) 10 likes 0 replies COTL1high NK cells are key determinants of checkpoint blockade responsiveness, with GITRL–GITR axis representing a
- Immune checkpoint therapy for solid tumours: clinical dilemmas and . . .
Immune-checkpoint inhibitors (ICBs), in addition to targeting CTLA-4, PD-1, and PD-L1, novel targeting LAG-3 drugs have also been approved in clinical application With the widespread use of the
- Therapeutic approaches to enhance natural killer cell cytotoxicity
We analyze a wide range of strategies, including cytokine-based treatment, monoclonal antibodies, and NK cell engagers, and discuss criteria that must be considered when selecting an NK cell product to combine with these strategies
|
|